Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menomune: A, C, Y, W 135 Meningococcal Polysaccharide
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide · 2 trials · 3 indications
Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia. Grade 3 reactions were defined as: Pain, headache, malaise, and myalgia - significant, prevents daily activity; Erythema and swelling - \> 100 mm; Fever, temperature of ≥ 39.0ºC or ≥ 102.1ºF.
Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, Myalgia, chills, Arthralgia, Urticaria, Anorexia, Diarrhea, and Vomiting.
Solicited injection site reactions: Pain, Erythema, and Swelling.
Solicited systemic reactions: Fever (temperature), Headache, Malaise, Myalgia, chills, Arthralgia, Urticaria, Anorexia, Diarrhea, and Vomiting.
| Arm | Type | Description |
|---|---|---|
| Menomune® vaccine group | EXPERIMENTAL | Participants received Menomune® vaccine in MTA29 (NCT00874549) |
| Menactra® vaccine group | EXPERIMENTAL | Participants received Menactra® vaccine in trial MTA29 (NCT00874549) |
| Group 1: Menomune Day 0 | ACTIVE_COMPARATOR | Participants received a single dose of Menomune® vaccine on Day 0. |
| Group 2: Menactra® Day 0 x 2 | EXPERIMENTAL | Participants received two single-dose injections of Menactra® vaccine on Day 0 |
| Group 3: Menactra® Day 0 and 14 | EXPERIMENTAL | Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14 |
| Group 4: Menactra® Day 0 and 28 | EXPERIMENTAL | Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28. |
| Name | Type | Description |
|---|---|---|
| Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate | BIOLOGICAL | 0.5 mL, Intramuscular |
| Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Menactra®: Polysaccharide Diphtheria Toxoid Conjugate | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged 56 years or older on the day of inclusion. * Received the appropriate Menactra or Menomune vaccine as assigned by randomization in Trial MTA29. * Ambulatory and healthy, as determined by medical history. * Informed consent form has been signed and dated. * Able to attend ...
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is used for the prevention of meningitis and meningococcal infections. It is a meningococcal polysaccharide vaccine directed against the A, C, Y, and W-135 serogroups. It is being developed by Sanofi and has been studied in older adults aged 56 years and above.
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of the vaccine, which targets meningitis and meningococcal infections.
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is in Phase 2 development. It is an investigational vaccine and is not approved. The clinical program includes one completed trial, with no active trials currently listed.
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide has been studied in two completed trials. NCT01239043 was a Phase 2 trial of antibody persistence and response to re-vaccination with Menactra or Menomune three years after initial vaccination. NCT00874549 was a Phase 1 safety and immunogenicity trial in subjects aged 56 years and older.
Yes. Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is also known as Menomune, including the variants Menomune A, C, Y, W 135 Meningococcal Polysaccharide. These names refer to the same Sanofi vaccine against meningococcal serogroups A, C, Y, and W-135.